Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis.
We determined serum concentrations of neopterin, soluble tumour necrosis factor (55 kDa) receptor (sTNF-R) and soluble interleukin-2 receptor (sIL-2R) in plasma of 44 patients with polymyositis (PM)/dermatomyositis (DM), including 15 patients with primary PM, 13 patients with primary DM, and 16 patients with myositis and systemic sclerosis in overlap. Concentrations of neopterin, sTNF-R and sIL-2R were measured using commercially available immunoassays. Serum neopterin was increased in 35 of 44 PM/DM patients (80%), sTNF-R in 14 (32%) and sIL-2R in 18 (41%) patients, respectively. There were significant correlations between serum neopterin and sTNF-R, sIL-2R and erythrocyte sedimentation rate (all P < 0.001). Neopterin, as well as sTNF-R and sIL-2R, did not correlate with clinical (neuromuscular and activities of daily living scores) and laboratory (creatine kinase levels) manifestations of myositis. Increased serum levels of neopterin were associated with non-muscular manifestations of PM/DM. In conclusion, serum neopterin appears to be a useful laboratory marker for ongoing immune activation and global disease activity in PM/DM.
Samsonov
M Y
MY
Cardiology Research Centre, Moscow, Russia.
Nassonov
E L
EL
Tilz
G P
GP
Geht
B M
BM
Demel
U
U
Gurkina
G T
GT
Shtutman
V Z
VZ
Guseva
A G
AG
Wachter
H
H
Fuchs
D
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers; D001708:Biopterins / Q000031:analogs & derivatives* / Q000097:blood; D003882:Dermatomyositis / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019798:Neopterin; D017285:Polymyositis / Q000097:blood*; D015375:Receptors, Interleukin-2 / Q000097:blood; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood; D012995:Solubility
D015415:Biomarkers; D015375:Receptors, Interleukin-2; D018124:Receptors, Tumor Necrosis Factor; D001708:Biopterins; D019798:Neopterin